Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 5/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | EDNRB | P24530 | 1/20 | 0.35 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1315672 | 0.85 | PRKAB2 (0.40) | KDM4EALDH1A1SMN1; SMN2TSHRMAPK1 | |
| SCHEMBL11023739 | 0.79 | NQO2 (0.48) | NQO2KDM4EPKMRCE1S1PR4 | |
| SCHEMBL30544220 | 0.79 | NQO2 (0.48) | NQO2KDM4EPKMRCE1S1PR4 | |
| SCHEMBL13843652 | 0.76 | NQO2 (0.41) | NQO2KDM4EPKMRCE1S1PR4 | |
| SCHEMBL1315299 | 0.75 | MAPK8 (0.43) | KDM4EPKMNPSR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1315093 | 0.74 | CHRM4 (0.40) | NQO2KDM4EPKMRCE1NPSR1 | |
| SCHEMBL12113616 | 0.73 | NPC1 (0.41) | KDM4EALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL1145385 | 0.73 | NQO2 (0.46) | NQO2KDM4EPKMALDH1A1GAA | |
| SCHEMBL13556488 | 0.72 | ALDH1A1 (0.42) | NQO2KDM4EALDH1A1MRGPRX4HSD17B10 | |
| SCHEMBL1505584 | 0.72 | MRGPRX4 (0.40) | NQO2KDM4EALDH1A1MRGPRX4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2375899-B1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES | ARRAY BIOPHARMA INC (US) | 2015-02-25 | — | — | EP | disclosed |
| EP-2375899-B1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES | ARRAY BIOPHARMA INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-11-10 | — | — | US | disclosed |
| EP-2375899-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | Array Biopharma, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010080864-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275608-A1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF | NOS1, NOS2, ASS1 | NQO2 442/4885KDM4E 1611/4885PKM 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.